Polylactide-polyglycolide Antibiotic Implants

Garvin, Kevin L.; Feschuk, Connie A

doi:10.1097/01.blo.0000175720.99118.fe

Cited by 103 publications

(60 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Bioactive ceramic scaffolds alone used in bone TE can serve as a delivery vehicle of drugs but the drug release patterns are difficult to control (Habraken et al 2007). On the other hand, biodegradable polymeric materials such as poly(lactic-co-glycolic acid) (PLGA) (Garvin & Feschuk 2005) and poly( propylene glycol-fumerate)/ methylmethacrylate (Gerhart et al 1993) can be used to control the local delivery of drugs; however, they show impaired osteoconduction and sometimes they provoke an adverse tissue response owing to inflammation as a consequence of acidic degradation (Böstman & Pihlajamäki 2000). Thus, the smart combination of bioceramics (including calcium phosphates (CaP), hydroxyapatite (HA) and silicate bioactive glasses (BGs)) and biodegradable polymers can not only improve the degradability of the inorganic material and alter its mechanical/physical properties (Rezwan et al 2006), but also drug-release profiles can be controlled to a greater extent than on pure ceramics (Habraken et al 2007).…”

Section: Introductionmentioning

confidence: 99%

Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds

Mouriño

Boccaccını

2009

J. R. Soc. Interface.

483

298

View full text Add to dashboard Cite

This paper provides an extensive overview of published studies on the development and applications of three-dimensional bone tissue engineering (TE) scaffolds with potential capability for the controlled delivery of therapeutic drugs. Typical drugs considered include gentamicin and other antibiotics generally used to combat osteomyelitis, as well as anti-inflammatory drugs and bisphosphonates, but delivery of growth factors is not covered in this review. In each case reviewed, special attention has been given to the technology used for controlling the release of the loaded drugs. The possibility of designing multifunctional three-dimensional bone TE scaffolds for the emerging field of bone TE therapeutics is discussed. A detailed summary of drugs included in three-dimensional scaffolds and the several approaches developed to combine bioceramics with various polymeric biomaterials in composites for drug-delivery systems is included. The main results presented in the literature are discussed and the remaining challenges in the field are summarized with suggestions for future research directions.

show abstract

Section: Introductionmentioning

confidence: 99%

Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds

Mouriño

Boccaccını

2009

J. R. Soc. Interface.

483

298

View full text Add to dashboard Cite

show abstract

“…15 Chronic osteomyelitis often requires surgical debridement or local antibiotic treatment. 15,16 Implanted antibiotic-impregnated beads have numerous advantages over systemic therapy. These include ease of placement, decreased systemic toxicity, reduced hospital stay, and less patient cost.…”

Section: Introductionmentioning

confidence: 99%

Antibiotic and chemotherapeutic enhanced three-dimensional printer filaments and constructs for biomedical applications

Weisman¹,

Nicholson²,

Tappa³

et al. 2015

IJN

View full text Add to dashboard Cite

Three-dimensional (3D) printing and additive manufacturing holds potential for highly personalized medicine, and its introduction into clinical medicine will have many implications for patient care. This paper demonstrates the first application of 3D printing as a method for the potential sustained delivery of antibiotic and chemotherapeutic drugs from constructs for patient treatment. Our design is focused on the on-demand production of anti-infective and chemotherapeutic filaments that can be used to create discs, beads, catheters, or any medical construct using a 3D printing system. The design parameters for this project were to create a system that could be modularly loaded with bioactive agents. All 3D-printed constructs were loaded with either gentamicin or methotrexate and were optimized for efficient and extended antibacterial and cancer growth-inhibiting cytostatic activity. Preliminary results demonstrate that combining gentamicin and methotrexate with polylactic acid forms a composite possessing a superior combination of strength, versatility, and enhanced drug delivery. Antibacterial effects and a reduction in proliferation of osteosarcoma cells were observed with all constructs, attesting to the technical and clinical viability of our composites. In this study, 3D constructs were loaded with gentamicin and methotrexate, but the method can be extended to many other drugs. This method could permit clinicians to provide customized and tailored treatment that allows patient-specific treatment of disease and has significant potential for use as a tunable drug delivery system with sustained-release capacity for an array of biomedical applications.

show abstract

“…The effectiveness of local antibiotic delivery using biodegradable polymers has been substantiated by in vitro and in vivo studies. The biodegradable polymers that have been studied include poly(D,L-lactic acid) 6,7) , polylactide-co-glycolide [8][9][10][11] , copolymers of L-lactide and DL-lactide 12) , polyanhydrides of bis-carboxyphenoxypropane and sebacic acid 13) , polycaprolactone [14][15][16] , and polyhydroxyalkanoate 17) . These antibiotic biodegradable polymers released antibiotics for several hours to 40 weeks in vitro and were effective for several weeks in vivo 18,19) .…”

Section: Introductionmentioning

confidence: 99%

Gatifloxacine-loaded PLGA and β-tricalcium phosphate composite for treating osteomyelitis

et al. 2011

View full text Add to dashboard Cite

Gatifloxacine (GFLX)-containing poly(lactide-co-glycolide) (PLGA) was introduced to the pores and surfaces of porous β-tricalcium phosphate (βTCP) granules by melt compounding whereby no toxic solvent was used. The granular composite of GFLX-loaded PLGA and βTCP released GFLX for 42 days in Hanks' balanced solution and exhibited sufficient in vitro bactericidal activity against Streptococcus milleri and Bacteroides fragilis for at least 21 days. For in vivo evaluation, the granular composite was implanted in the dead space created by the debridement of osteomyelitis lesion induced by S. milleri and B. fragilis in rabbit mandible. After a 4-week implantation, the inflammation area within the debrided area was markedly reduced accompanied with osteoconduction and vascularization in half of the rabbits, and even disappeared in one of the six rabbits without any systemic administration of antibiotics. Outside the debrided area, inflammation and sequestrum were observed but the largest of such affected areas amounted to only 0.125 times of the originally infected and debrided area. These findings showed that the granular composite was effective for the local treatment of osteomyelitis as well as an osteoconductive scaffold which supported and encouraged vascularization.

show abstract

Polylactide-polyglycolide Antibiotic Implants

Cited by 103 publications

References 31 publications

Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds

Bone tissue engineering therapeutics: controlled drug delivery in three-dimensional scaffolds

Antibiotic and chemotherapeutic enhanced three-dimensional printer filaments and constructs for biomedical applications

Gatifloxacine-loaded PLGA and β-tricalcium phosphate composite for treating osteomyelitis

Contact Info

Product

Resources

About